ClinicalTrials.gg
RecruitingNCT05915585Updated Jun 23, 2023

High-Intensity Laser Therapy for Eosinophilic Fasciitis

An interventional study of High-Intensity Laser Therapy in Eosinophilic Fasciitis, sponsored by Ahram Canadian University. Recruiting at 1 site in Egypt. Open to female participants. Per ClinicalTrials.gov, last updated 2023-06-23.

Sponsored by Ahram Canadian University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2023, 3 years 4 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Sex
Female
01

Study summary

Eosinophilic fasciitis (EF) is a rare musculoskeletal disorder characterized by inflammation and thickening of the fascia, leading to pain, stiffness, and functional impairment. Conventional treatment options include immunosuppressive medications, corticosteroids, and physical therapy. This case report will describe use of high-intensity laser therapy (HILT) using the Mectronic Exand MY high-intensity laser system in a patient with EF, highlighting its potential as an alternative or adjunct treatment option.

02

Conditions studied

  • Eosinophilic Fasciitis
03

In context

Lead sponsor

Ahram Canadian University is the lead sponsor of 71 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with Eosinophilic fasciitis.

Exclusion criteria

Exclusion Criteria:

  • a diagnosis unrelated to Eosinophilic fasciitis
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (estimated)

Study arms

  • Experimental
    High-Intensity Laser Therapy (HILT)

    Device: High-Intensity Laser Therapy

Interventions

  • DeviceHigh-Intensity Laser Therapy

    The patient will receive HILT using the Mectronic Exand MY high-intensity laser system with the following parameters: Wavelength: 1064 nm (near-infrared) Power: 12 W Energy density: 8 J/cm² Pulse duration: 200 µs Treatment duration: 10 minutes Frequency: 3 sessions per week for 4 weeks Total energy delivered: 96 J per treatment session

06

What researchers measure

Primary outcomes

  1. Pain intensity via Numeric pain rating scale

    Time frame: Changes in pain intensity at baseline and 4 weeks

  2. Functional outcomes via Disabilities of the Arm, Shoulder and Hand questionnaire (DASH)

    Time frame: Changes in DASH at baseline and 4 weeks

  3. Quality of life via Short Form-36 Health Survey

    Time frame: Changes in Short Form-36 Health Survey at baseline and 4 weeks

  4. Adverse event

    adverse events are recorded by the patient and therapist

    Time frame: 4 Weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2023; primary completion for Jul 2023, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2023
First posted
Jun 23, 2023
StartEst.
Jun 18, 2023
Primary completionEst.
Jul 19, 2023
CompletionEst.
Jul 20, 2023
Last update
Jun 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05915585
Lead sponsor
Ahram Canadian University
Responsible party
Mohamed Magdy ElMeligie (Lecturer of Physical Therapy and Director of Electromyography Lab, Ahram Canadian University) — Principal investigator
First posted
Jun 23, 2023
Start date
Jun 18, 2023 (estimated)
Primary completion
Jul 19, 2023 (estimated)
Completion
Jul 20, 2023 (estimated)
Last update
Jun 23, 2023

Study contacts

Mohamed M ElMeligie, Ph.d
Contact
mohamed.elmeligie@acu.edu.eg
+201064442032
Amal Fawzy, Ph.d
study director · Faculty of Physical Therapy, Ahram Canadian University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion